• Marianne Billeter, Marcus J Zervos, Anne Y Chen, Joseph R Dalovisio, and Changa Kurukularatne.
• Department of Infectious Diseases, Ochsner Clinic Foundation, New Orleans, Louisiana 70121, USA.
• Clin. Infect. Dis. 2008 Feb 15; 46 (4): 577-83.

AbstractThe increasing prevalence of drug-resistant gram-positive cocci, such as methicillin-resistant Staphylococcus aureus, has underscored the need for new agents for the treatment of this type of infection. Dalbavancin, a new lipoglycopeptide, has the desirable characteristics of increased in vitro activity, compared with vancomycin, for most gram-positive pathogenic bacteria, as well as an extremely long half-life, permitting once-weekly intravenous dosing. Clinical studies comparing linezolid with 2 doses of dalbavancin have shown comparable efficacy for the treatment of skin and soft-tissue infection. Dalbavancin has also proven to be effective for therapy of catheter-related bloodstream infections. It has an excellent safety profile in studies to date. Dalbavancin will likely have a significant role in outpatient intravenous therapy for patients with potentially serious drug-resistant gram-positive coccal infections.

20 keywords...

hide…